 |
|
|
| |
Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration
|
| |
| |
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy.
Washington DC, USA, 26-28 May 2015
Oral Presentation #3
Emi Tafoya, Yasong Lu , Melody Luo, Premkumar Narasimhan, Neelima Thanneer, Brenda Cirincione, Timothy Eley, Nannan Zhou, Dennis Hernandez, Fiona McPhee, Tarek Leil
Bristol-Myers Squibb, Princeton, NJ, USA; Bristol-Myers Squibb, Wallingford, CT, USA
EASL: Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study - (04/27/15)
|
| |
|
|
|
|
|
